U.S. Markets open in 7 hrs 50 mins
  • S&P Futures

    4,454.75
    -20.00 (-0.45%)
     
  • Dow Futures

    34,598.00
    -18.00 (-0.05%)
     
  • Nasdaq Futures

    14,699.75
    -141.25 (-0.95%)
     
  • Russell 2000 Futures

    2,020.50
    -0.70 (-0.03%)
     
  • Crude Oil

    86.29
    -0.61 (-0.70%)
     
  • Gold

    1,840.40
    -2.20 (-0.12%)
     
  • Silver

    24.56
    -0.16 (-0.65%)
     
  • EUR/USD

    1.1330
    +0.0013 (+0.1133%)
     
  • 10-Yr Bond

    1.8330
    0.0000 (0.00%)
     
  • Vix

    25.59
    +1.74 (+7.30%)
     
  • GBP/USD

    1.3585
    -0.0015 (-0.1128%)
     
  • USD/JPY

    113.8500
    -0.2500 (-0.2191%)
     
  • BTC-USD

    38,716.66
    -3,311.91 (-7.88%)
     
  • CMC Crypto 200

    915.45
    -79.81 (-8.02%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

Pliant Therapeutics to Participate in Piper Sandler Lung Day

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • PLRX

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a virtual fireside chat as part of the Piper Sandler Lung Day on Friday, October 15, 2021, at 11:00 a.m. ET.

A replay of the Piper Sandler virtual fireside chat will be available on the Events & Presentations page of Pliant’s website following the conclusion of the event for 90 days.

About Pliant Therapeutics, Inc.

Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to its development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook, and YouTube.


Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com